Skip to main content
. 2019 Nov 21;63(12):e01435-19. doi: 10.1128/AAC.01435-19

FIG 2.

FIG 2

Model 2-predicted effects of TDM in patients receiving posaconazole prophylaxis during GVHD. The effects of TDM-guided interventions with varied effectiveness are shown for quartiles of systemic posaconazole exposures (stacked bar graphs, left y axis) versus the average predicted probability ± standard deviation of clinical failure (plotted lines, right y axis) in patients receiving posaconazole suspension (a) or the extended-release tablet formulation (b).